-
公开(公告)号：US20130034578A1
公开(公告)日：2013-02-07
申请号：US13640178
申请日：2011-04-08
IPC: A61K39/145 , C12P21/00 , A61K31/7088 , A61P31/16 , C12N15/63
CPC classification number: A61K39/145 , A61K39/12 , A61K2039/5256 , A61K2039/552 , A61K2039/55566 , A61K2039/55577 , A61K2039/58 , A61K2039/70 , C07K2319/22 , C07K2319/73 , C12N9/2402 , C12N2760/16134 , C12N2760/18134 , C12N2760/18143 , C12N2770/20034 , C12Y302/01018
Abstract: The invention relates to immunogenic compositions comprising recombinant multimeric influenza proteins or parts thereof fused to a streptavidin affinity tag, preferably recombinant trimeric influenza virus hemagglutinin and/or recombinant tetrameric influenza virus neuraminidase, or vectors comprising nucleic acid sequences encoding such influenza proteins. The inventions further relate to methods for the preparation of such immunogenic compositions and uses thereof and methods for eliciting an immune response in an individual.
Abstract translation: 本发明涉及包含与链霉抗生物素蛋白亲和标签，优选重组三聚流感病毒血凝素和/或重组四聚流感病毒神经氨酸酶融合的重组多聚体流感蛋白或其部分的免疫原性组合物，或包含编码这种流感蛋白的核酸序列的载体。 本发明还涉及制备这种免疫原性组合物的方法及其用途以及在个体中引发免疫应答的方法。
-
公开(公告)号：US07556957B2
公开(公告)日：2009-07-07
申请号：US10714534
申请日：2003-11-14
IPC: C12N7/04 , A61K39/12 , A61K39/215
CPC classification number: A61K39/215 , A61K38/00 , A61K39/12 , A61K39/225 , A61K2039/5254 , A61K2039/5256 , A61K2039/5258 , A61K2039/552 , A61K2039/70 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2710/10034 , C12N2710/16334 , C12N2710/16734 , C12N2720/10034 , C12N2720/12234 , C12N2720/12334 , C12N2740/13034 , C12N2740/15034 , C12N2750/10034 , C12N2750/14334 , C12N2760/16134 , C12N2760/18134 , C12N2760/18434 , C12N2760/18534 , C12N2770/10034 , C12N2770/16034 , C12N2770/20021 , C12N2770/20022 , C12N2770/20023 , C12N2770/20034 , C12N2770/20043 , C12N2770/24334 , C12N2770/32134 , C12N2800/204 , G01N33/56983 , G01N2333/165
Abstract: The invention relates to the field of coronaviruses and diagnosis, therapeutic use, and vaccines derived therefrom. The invention provides replicative coronaviruses and virus-like particles (VLPs) from which large parts of their genome are (at least functionally) deleted without abolishing their replicative capacities. The deletion preferably results in at least a functional deletion in that the corresponding gene is not or is only partly expressed wherein the resulting gene product is dysfunctional or at least functionally distinct from a corresponding wild-type gene product. One result seen with VLPs provided with deletions as provided herein is that the deleted VLP, albeit capable of replication in vitro and in vivo, are generally well attenuated, in that they do not cause disease in the target host, making them very suitable for therapeutic use, such as a delivery vehicle for genes and other cargo (wherein specific targeting may be provided as well when desired), and for use as a vaccine, being attenuated while carrying important immunogenic determinants that help elicit an immune response.
Abstract translation: 本发明涉及冠状病毒和诊断领域，治疗用途以及从其衍生的疫苗。 本发明提供复制性冠状病毒和病毒样颗粒（VLP），其基因组的大部分（至少在功能上）被删除，而不消除其复制能力。 缺失优选至少导致功能缺失，因为相应的基因不是或仅部分表达，其中所得基因产物在相应的野生型基因产物中功能失调或至少在功能上不同。 在本文提供的具有缺失的VLP所见的一个结果是缺失的VLP虽然在体外和体内都能复制，但通常是很好的减毒，因为它们不会在靶宿主中引起疾病，使得它们非常适合于治疗 使用，例如用于基因和其他货物的递送载体（其中当需要时可以提供特异性靶向），并用作疫苗，同时携带有助于引发免疫应答的重要的免疫原性决定簇。
-
3.发明授权Immunogenic compositions in particulate form and methods for producing the same 有权颗粒形式的免疫原性组合物及其制备方法公开(公告)号：US09585953B2
公开(公告)日：2017-03-07
申请号：US14006121
申请日：2012-03-22
Applicant: Cornelis Johannes Leenhouts , Bert Jan Haijema , Maarten Leonardus van Roosmalen , Petrus Josephus Marie Rottier , Cornelis Alexander Maria de Haan , Berend Jan Bosch
Inventor： Cornelis Johannes Leenhouts , Bert Jan Haijema , Maarten Leonardus van Roosmalen , Petrus Josephus Marie Rottier , Cornelis Alexander Maria de Haan , Berend Jan Bosch
IPC: A61K39/385 , A61K39/145 , A61K39/155 , C07K14/005 , A61K47/48 , C12N9/36 , A61K39/12 , A61K39/00
CPC classification number: A61K39/385 , A61K39/12 , A61K39/145 , A61K39/155 , A61K47/646 , A61K2039/543 , A61K2039/55505 , A61K2039/6068 , C07K14/005 , C07K2319/20 , C07K2319/33 , C07K2319/40 , C07K2319/70 , C07K2319/73 , C12N9/2462 , C12N2760/16122 , C12N2760/16134 , C12N2760/18522 , C12N2760/18534 , C12Y302/01017
Abstract: The invention relates to the field of immunology and vaccine development, in particular to the development of vaccines based on native antigen oligomers. Provided is an immunogenic composition in particulate form, comprising oligomers of a surface exposed polypeptide of pathogenic origin or tumor origin, or antigenic part thereof, said oligomers being bound non-covalently to a particulate carrier, and a pharmaceutically acceptable diluent or excipient. Also provided is a recombinant polypeptide comprising (A) an N- or C-terminal antigenic domain, comprising at least one surface exposed polypeptide of pathogenic or tumor origin, or antigenic part thereof, the antigenic domain being fused to (B) an oligomerization domain (OMD), said oligomerization domain being fused via (C) a linker domain to (D) a peptidoglycan binding domain (PBD) consisting of a single copy of a LysM domain capable of mediating the non-covalent attachment of the polypeptide to a non-viable bacterium-like particle (BLP) obtained from a Gram-positive bacterium.
Abstract translation: 本发明涉及免疫学和疫苗开发领域，特别涉及基于天然抗原寡聚体的疫苗的开发。 本发明提供了一种颗粒形式的免疫原性组合物，其包含病原起源或肿瘤来源的表面暴露多肽的寡聚体或其抗原部分，所述寡聚物非共价结合至颗粒状载体，以及药学上可接受的稀释剂或赋形剂。 还提供了包含（A）N-或C-末端抗原结构域的重组多肽，其包含至少一种表面暴露的病原性或肿瘤来源的多肽或其抗原部分，所述抗原结构域与（B）寡聚化结构域 （OMD），所述寡聚结构域通过（C）连接体结构域融合到（D）由能够将多肽非共价连接到非非共价连接的LysM结构域的单拷贝组成的肽聚糖结合结构域（PBD） 从革兰氏阳性菌获得的可行的细菌样颗粒（BLP）。
-
4.发明申请Immunogenic Compositions In Particulate Form And Methods For Producing The Same 有权颗粒形式的免疫原性组合物及其生产方法公开(公告)号：US20140093532A1
公开(公告)日：2014-04-03
申请号：US14006121
申请日：2012-03-22
Applicant: Cornelis Johannes Leenhouts , Bert Jan Haijema , Maarten Leonardus Van Roosmalen , Petrus Josephus Marie Rottier , Cornelis Alexander Maria De Haan , Berend Jan Bosch
Inventor： Cornelis Johannes Leenhouts , Bert Jan Haijema , Maarten Leonardus Van Roosmalen , Petrus Josephus Marie Rottier , Cornelis Alexander Maria De Haan , Berend Jan Bosch
IPC: A61K39/385 , C07K14/005 , A61K47/48
CPC classification number: A61K39/385 , A61K39/12 , A61K39/145 , A61K39/155 , A61K47/646 , A61K2039/543 , A61K2039/55505 , A61K2039/6068 , C07K14/005 , C07K2319/20 , C07K2319/33 , C07K2319/40 , C07K2319/70 , C07K2319/73 , C12N9/2462 , C12N2760/16122 , C12N2760/16134 , C12N2760/18522 , C12N2760/18534 , C12Y302/01017
Abstract: The invention relates to the field of immunology and vaccine development, in particular to the development of vaccines based on native antigen oligomers. Provided is an immunogenic composition in particulate form, comprising oligomers of a surface exposed polypeptide of pathogenic origin or tumour origin, or antigenic part thereof, said oligomers being bound non-covalently to a particulate carrier, and a pharmaceutically acceptable diluent or excipient. Also provided is a recombinant polypeptide comprising (A) an N- or C-terminal antigenic domain, comprising at least one surface exposed polypeptide of pathogenic or tumour origin, or antigenic part thereof, the antigenic domain being fused to (B) an oligomerization domain (OMD), said oligomerization domain being fused via (C) a linker domain to (D) a peptidoglycan binding domain (PBD) consisting of a single copy of a LysM domain capable of mediating the non-covalent attachment of the polypeptide to a non-viable bacterium-like particle (BLP) obtained from a Gram-positive bacterium.
Abstract translation: 本发明涉及免疫学和疫苗开发领域，特别涉及基于天然抗原寡聚体的疫苗的开发。 本发明提供了一种颗粒形式的免疫原性组合物，其包含病原起源或肿瘤来源的表面暴露多肽的寡聚体或其抗原部分，所述寡聚物非共价结合至颗粒状载体，以及药学上可接受的稀释剂或赋形剂。 还提供了包含（A）N-或C-末端抗原结构域的重组多肽，其包含至少一种表面暴露的病原性或肿瘤来源的多肽或其抗原部分，所述抗原结构域与（B）寡聚化结构域 （OMD），所述寡聚结构域通过（C）连接体结构域融合到（D）由能够将多肽非共价连接到非非共价连接的LysM结构域的单拷贝组成的肽聚糖结合结构域（PBD） 从革兰氏阳性菌获得的可行的细菌样颗粒（BLP）。
-
-
-
Search Results
4
records
(took 0.02 seconds)
